A recent study suggests that Britain’s agreement on drug pricing with the US, driven by President Trump’s demands, could result in a higher death toll than the Covid-19 pandemic if National Health Service (NHS) funds are redirected to cover the costs. The analysis, conducted by experts at Liverpool University, indicates that diverting around £45 billion from NHS funds to pay American drug companies higher prices could lead to 229,000 preventable deaths by 2036.
President Trump had threatened to impose substantial tariffs on drug imports, particularly from UK companies, if the NHS did not opt for pricier medications from US firms. The NHS, known for its effective negotiation of lower prices compared to private hospitals in the US, might face a significant financial strain under this deal.
The study, published in the British Medical Journal, warns that without additional funding to bridge the financial gap, the potential increase in preventable deaths could reach up to 291,000 by 2036, surpassing the death toll from Covid-19 during the same period. The authors emphasize the critical need for transparent decision-making regarding healthcare resource allocation and the impact of opportunity costs in such scenarios.
The government’s commitment to doubling spending on new medicines to at least 0.6% of the gross domestic profit (GDP) by 2036 under this deal raises concerns about the affordability and accessibility of vital healthcare services. While this agreement may facilitate the approval of expensive drugs like immunotherapy treatments for cancer, the lack of sufficient funds could strain NHS resources, affecting staff and essential infrastructure.
Furthermore, the study highlights that the deal could lead to a rise in medicine prices without significantly expanding the range of drugs prescribed, potentially limiting access to affordable healthcare. The government’s decision to accommodate industry demands amidst pressure from pharmaceutical giants has sparked calls for greater transparency and accountability, urging the publication of the full details and impact assessment of the trade deal.
Campaigners in the UK have raised objections to the agreement, expressing concerns about its potential negative impact on public health and the economy. The lack of parliamentary scrutiny and transparency surrounding the deal has prompted calls for a reassessment of the government’s approach to healthcare funding and policy decisions.
As the debate continues, stakeholders are urging a reevaluation of the deal’s implications on the NHS and the broader healthcare sector, emphasizing the importance of prioritizing public health and well-being over industry demands.